Mandate

Vinge has advised CELLINK in connection with directed issues of SEK 3 billion

Vinge has advised CELLINK AB (publ) in connection with a directed issue of covertibles of SEK 1.5 billion and a directed issue of B-shares of SEK 1.5 billion, in total SEK 3 billion.

The convertibles and the shares have been offered by way of an accelerated bookbuilding process arranged by Citigroup Global Markets, J.P. Morgan and Carnegie Investment Bank. The convertibles and shares were subscribed for by Swedish and international institutional investors.

Vinge’s team has consisted of Anders Strid, Edin Agic, Hampus Olsson, Linus Adolfsson and Maria Schultzberg (tax). Sullivan & Cromwell has advised Cellink in relation to English and US laws.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026